Answers are grounded in this paper and cite their sources.
Clinical trial shows gedatolisib plus fulvestrant improves outcomes in hormone receptor-positive breast cancer, suggesting a new treatment option.
The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor-positive/HER2-, PIK3CA WT advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Hurvitz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: